[go: up one dir, main page]

MX2009003301A - Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas. - Google Patents

Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas.

Info

Publication number
MX2009003301A
MX2009003301A MX2009003301A MX2009003301A MX2009003301A MX 2009003301 A MX2009003301 A MX 2009003301A MX 2009003301 A MX2009003301 A MX 2009003301A MX 2009003301 A MX2009003301 A MX 2009003301A MX 2009003301 A MX2009003301 A MX 2009003301A
Authority
MX
Mexico
Prior art keywords
nimiv
rhinovirus
novel
vaccine applications
neutralizing immunogen
Prior art date
Application number
MX2009003301A
Other languages
English (en)
Inventor
Kirill Kalnin
Yanhua Yan
Harold Kleanthous
Original Assignee
Sanofi Pasteur Biologics Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics Co filed Critical Sanofi Pasteur Biologics Co
Publication of MX2009003301A publication Critical patent/MX2009003301A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K16/106—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere a métodos y composiciones para prevenir o tratar infección de rhinovirus humano.
MX2009003301A 2006-09-29 2007-10-01 Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas. MX2009003301A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84845106P 2006-09-29 2006-09-29
PCT/US2007/021053 WO2008057158A2 (en) 2006-09-29 2007-10-01 Novel neutralizing immunogen (nimiv) of rhinovirus and its use for vaccine applications

Publications (1)

Publication Number Publication Date
MX2009003301A true MX2009003301A (es) 2009-07-15

Family

ID=39364960

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003301A MX2009003301A (es) 2006-09-29 2007-10-01 Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas.

Country Status (12)

Country Link
US (2) US8652486B2 (es)
EP (2) EP2548573A1 (es)
JP (1) JP2010504759A (es)
KR (1) KR20090092764A (es)
CN (1) CN101678095B (es)
AU (1) AU2007318206A1 (es)
BR (1) BRPI0719443A2 (es)
CA (1) CA2664628C (es)
IL (1) IL197755A (es)
MX (1) MX2009003301A (es)
WO (1) WO2008057158A2 (es)
ZA (1) ZA200901993B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2069483A4 (en) * 2006-09-29 2010-10-27 Sanofi Pasteur Biologics Co RECOMBINANT RHINOVIRAL VECTORS
WO2009120380A2 (en) * 2008-03-27 2009-10-01 Sanofi Pasteur Biologics Co. Recombinant rhinovirus vectors
EP2316481A1 (en) 2009-10-30 2011-05-04 Biomay Ag Pharmaceutical composition for the treatment and prevention of a rhinovirus infection
GB201115910D0 (en) 2011-09-14 2011-10-26 Univ Manchester Peptides
EP3608332B1 (en) 2013-03-15 2022-06-01 GlaxoSmithKline Biologicals SA Vaccine against human rhinovirus
EP2970396B1 (en) * 2013-03-15 2022-02-23 Biological Mimetics, Inc. Immunogenic human rhinovirus (hrv) compositions
US11160857B2 (en) * 2015-06-15 2021-11-02 Emory University Multivalent enterovirus vaccine compositions and uses related thereto
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0169146A3 (en) 1984-07-20 1988-07-20 Merck & Co. Inc. Monoclonal antibodies directed against the cellular receptor of human rhinovirus
JPS6147191A (ja) * 1984-07-20 1986-03-07 メルク　エンド　カムパニー　インコーポレーテッド ヒト・ライノウイルスｒｎａおよびたんぱく
US5541100A (en) * 1990-09-12 1996-07-30 Rutgers University Chimeric rhinoviruses
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20040146524A1 (en) 2002-02-21 2004-07-29 Katelynne Lyons Stabilized immunogenic HBc chimer particles
US7429472B2 (en) * 2003-01-31 2008-09-30 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
KR20070057954A (ko) * 2004-09-28 2007-06-07 알자 코포레이션 알룸-애주번트가 있는 면역 활성제의 안정화
US8153760B2 (en) * 2005-01-19 2012-04-10 Donald Danforth Plant Science Center Rhinovirus vaccines

Also Published As

Publication number Publication date
CN101678095A (zh) 2010-03-24
IL197755A0 (en) 2011-08-01
AU2007318206A2 (en) 2009-06-04
US20140161833A1 (en) 2014-06-12
WO2008057158A9 (en) 2008-09-18
JP2010504759A (ja) 2010-02-18
EP2548573A1 (en) 2013-01-23
CN101678095B (zh) 2013-04-24
CA2664628C (en) 2016-08-09
US9381237B2 (en) 2016-07-05
CA2664628A1 (en) 2008-05-15
EP2066343A4 (en) 2010-05-19
KR20090092764A (ko) 2009-09-01
EP2066343B1 (en) 2017-06-14
WO2008057158A2 (en) 2008-05-15
WO2008057158A3 (en) 2008-08-07
BRPI0719443A2 (pt) 2013-12-10
US20100297169A1 (en) 2010-11-25
EP2066343A2 (en) 2009-06-10
IL197755A (en) 2015-09-24
US8652486B2 (en) 2014-02-18
AU2007318206A1 (en) 2008-05-15
ZA200901993B (en) 2010-07-28

Similar Documents

Publication Publication Date Title
MX2009003301A (es) Novedoso inmunogeno neutralizante (nimiv) de rhinovirus y su uso para aplicaciones de vacunas.
CR11731A (es) Composiciones y procedimientos para su preparación y uso
EA200970529A1 (ru) Антивирусная композиция и способ ее применения
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CL2007001847A1 (es) Composicion farmaceutica intramuscular o subcutanea que comprende tmc278 (rilpivirina); proceso para preparar la composicion; y uso para el tratamiento o prevencion de infeccion por vih.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CY1110900T1 (el) Χημικες ενωσεις
CY1108275T1 (el) Χημικες ενωσεις
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
EA200901490A1 (ru) Химические соединения
CR20140392A (es) Dihidropirazolonas sustituidas
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
CL2007001392A1 (es) Compuestos derivados de quinolina o benzopirano inhibidores de la replicacion del hiv; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una infeccion por vih
BRPI0820568A2 (pt) Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
CL2008001367A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion bacteriana.
ECSP109968A (es) Depsipéptidos cíclicos
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
CL2008003712A1 (es) Compuestos derivados de tiadiazololoxifenilamidina o tiazoliloxifenilamidina; su procedimiento de preparacion; uso y procedimiento para combatir microorganismos no deseados; agente que comprende a dichos compuestos; compuestos intermediarios; y su procedimiento de preparacion.
ATE503769T1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
BRPI0819839A2 (pt) Uso de anticorpo humano capaz de neutralizar o vírus da hepatite b para a prevenção ou tratamento da infecção por vírus da hepatite b
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto
BRPI0910884A2 (pt) composição imunogênica, método para tratar ou prevenir infecção ou doença estafilocócicas, e, uso de uma composição imunogênica.
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso

Legal Events

Date Code Title Description
HH Correction or change in general